PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

Seven-year follow-up data show that transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement have ...

If you know what a TAVR procedure is; a shiny gold star for you. And if you know why, at Overlake Medical Center, they call the second day of the work week “TAVR Tuesdays,” you get two gold stars. And ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA. At ...